Where Innovations Meets Personalized and Precision Medicine
Keywords = Autoimmune disease
Number of Articles: 3
Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Volume 11, Issue 40, Winter 2026, Pages 16-25

https://doi.org/10.22034/ppmj.2026.2066237.1066

Ramesh Ranjbar, Ramin Shukripour

Abstract Rheumatoid arthritis (RA) is an irreversible systemic autoimmune disorder. The advancement of the illness results in joint deformity and associated functional impairment, which profoundly impacts the standard of life of those affected. This review offers an overview of rheumatoid arthritis (RA), including a broad introduction to the illness, its epidemiology, associated risks, and pathogenesis. It also emphasizes advancements in fundamental research and the many mechanisms of signaling and molecular processes, including genetic variables. Summary of previous studies: In recent decades, researchers have garnered more interest in rheumatoid arthritis. Aberrant signaling pathways in rheumatoid arthritis (RA) constitute a significant area of study for identifying and treating the condition, offering crucial insights for comprehending this complex illness and formulating relevant therapies. The etiology of rheumatoid arthritis is associated with several signaling pathways. Research has repeatedly examined the etiology of rheumatoid arthritis (RA), revealing that both environmental and genetic variables play significant roles in its onset. Additionally, several research indicates that the susceptibility and severity of rheumatoid arthritis (RA) may correlate with the HLA-DRB1 variant, which exhibits the most significant genetic relationship with RA.

Relationship between LncRNAs and Multiple Sclerosis (MS)

Relationship between LncRNAs and Multiple Sclerosis (MS)

Volume 8, Issue 28, Winter 2023, Pages 13-19

https://doi.org/10.22034/pmj.2023.702081

Reyhaneh Tahouri, Ghasem Ghorbani Valezaghard

Abstract Multiple sclerosis (MS), the most common inflammatory demyelinating illness of the central nervous system (CNS), presents a range of clinical symptoms. The body’s immune system attacking myelin causes the transmission block in MS, which increases the electrical capacity of axons. Studies suggest that epigenetic factors play a part in the development of MS. Longer than 200 nucleotides in length and widely distributed, lncRNAs are linear RNA transcripts that cannot code for proteins. For instance, evidence suggests that lncRNAs are essential for a number of cellular functions, including immune response regulation, epithelial mesenchymal transition (EMT), cancer cell proliferation and metastasis, cellular homeostasis, and embryonic development. Epigenetic mechanisms have been proven to have a significant impact on the pathophysiology of MS, and their participation has revealed the function of lncRNAs as epigenetic regulatory molecules in molecular processes. The major subjects of this study have been the relationship between lncRNAs and MS, the role of lncRNA in the pathophysiology of the disease, and the diagnostic and prognostic potential of lncRNA in MS.

miR-22-3p as a Novel Biomarker in Rheumatoid Arthritis

miR-22-3p as a Novel Biomarker in Rheumatoid Arthritis

Volume 7, Issue 24, 2022, Pages 19-22

https://doi.org/10.22034/pmj.2022.252479

Maryam Hassanpoor, Bahareh Abbasi

Abstract Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune. Early diagnosis of RA remains challenging. A significant portion of RA patients also experience unremitting symptoms despite treatment. miRNA are involved in the regulation of autoimmunity- and inflammation-related processes. In this study, we evaluated the expression of miR-22-3p in serum of RA patients as a novel biomarker. Expression level of this gene in the blood serum of 30 people with RA compared with 30 healthy individuals by the qRT-PCR method. Results showed levels of miR22-3p were significantly higher in the serum of patients with RA in comparison with healthy control (p<0.0001). We suggest that miR 22-3p can be used as a biomarker in early detection and screening.